Related Experiment Video

Updated: Jun 9, 2026

Isolated Pancreatic Islet Treatment and Apoptosis Measurement
09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

Concurrently using rosiglitazone prevents glucosamine-induced islet beta-cell apoptosis and dysfunction

Xinxia Zhang1, Nanwei Tong, Yao Li

  • 1Division of Teaching & Research in Western Internal Medicine, Clinical College, Chengdu University of Traditional Chinese Medicine, China.

Cell Biochemistry and Function
|August 31, 2010
PubMed

Insights

Rosiglitazone (RSG) protects islet beta cells from glucosamine (GlcN)-induced apoptosis and dysfunction. This study demonstrates RSG

Area of Science:

  • Endocrinology
  • Cell Biology
  • Pharmacology

Background:

  • Diabetes mellitus is a major global health concern.
  • Glucosamine (GlcN) is used in diabetes management but can induce islet beta cell toxicity.
  • Understanding GlcN-induced beta cell damage is crucial for therapeutic strategies.

Purpose of the Study:

  • To investigate the protective effects of rosiglitazone (RSG) against glucosamine (GlcN)-induced apoptosis and dysfunction in islet beta cells.
  • To elucidate the molecular mechanisms underlying RSG's protective action.

Main Methods:

  • Utilized the HIT-T15 islet beta cell line.
  • Administered GlcN to induce apoptosis and dysfunction.
  • Assessed cell viability, apoptosis markers (Bcl-2, Bcl-xL, Bax, Bid, caspase-3), ATP production, and insulin secretion.
  • Evaluated the effects of co-treatment with RSG and GlcN.

Main Results:

  • GlcN induced HIT-T15 cell death through apoptosis, altering Bcl-2 family protein expression and increasing caspase-3 activity.
  • GlcN treatment reduced ATP production and insulin secretion in a dose-dependent manner.
  • Concurrent administration of RSG with GlcN significantly abrogated these GlcN-induced pathogenic changes.

Conclusions:

  • Rosiglitazone (RSG) effectively inhibits glucosamine (GlcN)-induced apoptosis and dysfunction in islet beta cells.
  • RSG may prevent GlcN-related complications in diabetes treatment by protecting beta cell function.
  • This finding supports the potential therapeutic benefit of combining RSG with GlcN in managing diabetes.

More Related Videos

Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator06:08

Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator

Published on: May 19, 2023

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.